# Brentuximab Vedotin for Systemic Sclerosis

> **NCT03222492** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 17 (actual)

## Conditions studied

- Diffuse Cutaneous Systemic Sclerosis
- Scleroderma
- dcSSc

## Interventions

- **BIOLOGICAL:** Brentuximab Vedotin
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03222492
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-20
- **Primary completion:** 2023-04-10
- **Final completion:** 2023-04-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03222492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03222492, "Brentuximab Vedotin for Systemic Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03222492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*